Navigation Links
Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas
Date:3/25/2011

HOUSTON, March 25, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program.   The award will fund personnel, manufacturing, and clinical testing of Bellicum's CaspaCIDe™ therapy, which promises to substantially improve outcomes for late stage cancer patients.

CPRIT was established to expedite cancer research innovation and commercialization and to enhance access to evidence-based prevention programs and services throughout the State. Company commercialization awards are a critical part of the Institute's initiative to support the advancement of the most promising opportunities towards regulatory approval and market launch.  The State has announced more than $500 million in awards and matching funds for innovative cancer research and prevention programs.

The application review process included in-depth evaluation by scientific and commercialization experts, followed by regulatory, product development and intellectual property due diligence. Acceptance of the award is subject to the completion of contract negotiations.  "We are pleased to have been recommended for a significant $5.7 million award from CPRIT to advance our novel therapy for patients with high risk cancers," said CEO Tom Farrell. "We are especially pleased to receive this notice given the rigorous review of our application by the CPRIT Commercialization Review Council, whose members have substantial scientific, venture capital and commercial expertise."

The award will support clinical development of CaspaCIDe™, Bellicum's solution to the problem of Graft versus Host Disease (GvHD), a debilitating and often fatal side effect of bone marrow transplantation. Originally developed by Bellicum CSO Dr. David Spencer, Vice Chair of Pathology and Immunology at Baylor College of Medicine, and advanced into clinical trials by Dr. Malcolm Brenner, Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, CaspaCIDe™ works by allowing the transplant physician to selectively eliminate transplanted cells that cause GvHD. Building on promising early clinical results seen in Dr. Brenner's "CASPALLO" trial, the CPRIT award will support the execution of a randomized, double-blind clinical trial in patients with high risk hematologic malignancies.

"For cancer patients with high risk leukemias and lymphomas, a bone marrow transplant offers a chance of a cure, but mortality from the procedure is high," stated Bellicum Founder, Chairman and CMO Dr. Kevin Slawin. "In this application, CaspaCIDe™ provides a rapid and effective means to resolve GvHD, the number one problem facing transplant patients and their physicians today.  More broadly, it has the potential to transform medicine by enabling a wide range of new, safer, more effective cell therapies."

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing clinical applications of chemical induction of dimerization (CID), a drug-based remote control technology that extends the physician's reach beyond the point at which a treatment has been administered. Bellicum's mission is to leverage this smart technology to bring safe, effective, innovative cell therapies to market for patients with serious and life threatening diseases. The company's DeCIDe™ vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific T cell immune response. Lead product BPX-101, an autologous DeCIDe™ vaccine, is in clinical development for patients with metastatic castrate resistant prostate cancer (mCRPC). CaspaCIDe™ is a cell therapy safety switch, permitting the rapid elimination of cells in the event of toxicity. CaspaCIDe™ DLI is a donor lymphocyte infusion administered following a hematopoietic stem cell transplant, in which the safety switch may be activated to resolve graft vs. host disease (GvHD). For more information, visit http://www.bellicum.com.


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
2. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
3. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
4. Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
5. Reportlinker Adds Process Analytical Technologies for Pharmaceuticals: Global Markets
6. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
7. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
8. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
9. Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
10. Inovio Pharmaceuticals Receives U.S. DOD Small Business Innovation Research Grant for Multi-Vaccine DNA Delivery Device Development
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):